Eovist approved as contrast for hepatic MRI

Eovist (gadoxetate disodium injection, from Bayer), a liver-specific magnetic resonance imaging (MRI) contrast agent, has been approved to detect and characterize lesions in adults with known or suspected focal liver disease.

Eovist enhances healthy liver tissue (parenchymal enhancement) for imaging while lesions with no or minimal hepatic function (e.g., cysts, metastases, hepatocellular carcinomas) remain unenhanced by Eovist and therefore more readily detected.

For more information call (888) 84-BAYER or visit www.Imaging.BayerHealthCare.com.